10X Genomics Inc
NASDAQ:TXG

  • LAST PRICE
    17.3200
  • TODAY'S CHANGE (%)
    -0.1700 (-0.9720%)
  • Bid / Lots
    17.3500/ 1
  • Ask / Lots
    17.6500/ 3
  • Open / Previous Close
    17.5200 / 17.4900
  • Day Range
    16.9300
    17.6600
  • 52 Week Range
    15.2800
    63.5700
  • Volume
    1,927,671

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Medical Equipment, Supplies & Distribution Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TXG
10X Genomics Inc
2.1B
-7.7x
---
WRBY
Warby Parker Inc
1.9B
-35.0x
---
NVCR
Novocure Ltd
1.9B
-10.0x
---
MYGN
Myriad Genetics Inc
2.4B
-9.4x
---
UFPT
UFP Technologies Inc
2.3B
50.2x
+24.81%
STAA
STAAR Surgical Co
2.3B
146.2x
+31.52%
As of 2024-07-15

Company Information

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Contact Information

Headquarters
6230 Stoneridge Mall RoadPLEASANTON, CA, United States 94588
Phone
925-401-7300
Fax
302-655-5049

Executives

Independent Chairman of the Board
John Stuelpnagel
President, Co-Founder, Chief Scientific Officer, Director
Benjamin Hindson
Chief Executive Officer, Co-Founder, Director
Serge Saxonov
Chief Financial Officer
Justin Mcanear
Chief Legal Officer
Eric Whitaker

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.1B
Revenue (TTM)
$625.4M
Shares Outstanding
119.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.83
EPS
$-2.24
Book Value
$6.22
P/E Ratio
-7.7x
Price/Sales (TTM)
3.3
Price/Cash Flow (TTM)
---
Operating Margin
-43.94%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.